CHIARA Calabrese

Dr. CHIARA Calabrese


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Leukemia Research
Verified
Journal Article
Closed access
Jessica PetitiJessica Petiti
Jessica Petiti
VRValentina Rosso
Valentina Rosso
MIMarco Lo Iacono
Marco Lo Iacono
CCCHIARA Calabrese
CHIARA Calabrese
ESElisabetta Signorino
Elisabetta Signorino
DCDaniela Cilloni
Daniela Cilloni

19 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Muhammad Shahzad AliMuhammad Shahzad Ali
Muhammad Shahzad Ali
cristina panuzzocristina panuzzo
cristina panuzzo
CCCHIARA Calabrese
CHIARA Calabrese
AMAlessandro Maglione
Alessandro Maglione
RPRocco Piazza
Rocco Piazza
Enrico BraccoEnrico Bracco
Enrico Bracco
HERC E3 subfamily members are parts of the E3 ubiquitin ligases and key players for a wide range of cellular functions. Though the involvement of the Ubiquitin Proteasome System in blood disorders has been broadly studied, so far the role of large HERCs in this context remains unexplored. In the present study we examined the expression of the large HECT E3 Ubiquitin Ligase, HERC1, in blood disorders. Our findings revealed that HERC1 gene expression was severely downregulated both in acute and in chronic myelogenous leukemia at diagnosis, while it is restored after complete remission achievement. Instead, in Philadelphia the negative myeloproliferative neoplasm HERC1 level was peculiarly controlled, being very low in Primary Myelofibrosis and significantly upregulated in those Essential Thrombocytemia specimens harboring the mutation in the calreticulin gene. Remarkably, in CML cells HERC1 mRNA level was associated with the BCR-ABL1 kinase activity and the HERC1 protein physically interacted with BCR-ABL1. Furthermore, we found that HERC1 was directly tyrosine phosphorylated by the ABL kinase. Overall and for the first time, we provide original evidence on the potential tumor-suppressing or -promoting properties, depending on the context, of HERC1 in myeloid related blood disorders.

14 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MIMarco Lo Iacono
Marco Lo Iacono
ESElisabetta Signorino
Elisabetta Signorino
Jessica PetitiJessica Petiti
Jessica Petiti
MPMonica Pradotto
Monica Pradotto
CCCHIARA Calabrese
CHIARA Calabrese
DCDaniela Cilloni
Daniela Cilloni
Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome that originates from the reciprocal translocation t(9;22)(q34;q11.2) and encodes for the constitutively active tyrosine kinase protein BCR-ABL1 from the Breakpoint Cluster Region (BCR) sequence and the Abelson (ABL1) gene. Despite BCR-ABL1 being one of the most studied oncogenic proteins, some molecular mechanisms remain enigmatic, and several of the proteins, acting either as positive or negative BCR-ABL1 regulators, are still unknown. The Drosophila melanogaster represents a powerful tool for genetic investigations and a promising model to study the BCR-ABL1 signaling pathway. To identify new components involved in BCR-ABL1 transforming activity, we conducted an extensive genetic screening using different Drosophila mutant strains carrying specific small deletions within the chromosomes 2 and 3 and the gmrGal4,UAS-BCR-ABL1 4M/TM3 transgenic Drosophila as the background. From the screening, we identified several putative candidate genes that may be involved either in sustaining chronic myeloid leukemia (CML) or in its progression. We also identified, for the first time, a tight connection between the BCR-ABL1 protein and Rab family members, and this correlation was also validated in CML patients. In conclusion, our data identified many genes that, by interacting with BCR-ABL1, regulate several important biological pathways and could promote disease onset and progression.